Gazda Hanna T, Zhong Rong, Long Lilia, Niewiadomska Edyta, Lipton Jeffrey M, Ploszynska Anna, Zaucha Jan M, Vlachos Adrianna, Atsidaftos Evangelia, Viskochil David H, Niemeyer Charlotte M, Meerpohl Joerg J, Rokicka-Milewska Roma, Pospisilova Dagmar, Wiktor-Jedrzejczak W, Nathan David G, Beggs Alan H, Sieff Colin A
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA.
Br J Haematol. 2004 Oct;127(1):105-13. doi: 10.1111/j.1365-2141.2004.05152.x.
The genetic basis of Diamond-Blackfan anaemia (DBA), a congenital erythroid hypoplasia that shows marked clinical heterogeneity, remains obscure. However, the fact that nearly one-quarter of patients harbour a variety of mutations in RPS19, a ribosomal protein gene, provides an opportunity to examine whether haplo-insufficiency of RPS19 protein can be demonstrated in certain cases. To that end, we identified 19 of 81 DBA index cases, both familial and sporadic, with RPS19 mutations. We found 14 distinct insertions, deletions, missense, nonsense and splice site mutations in the 19 probands, and studied mutations in 10 patients at the RNA level and in three patients at the protein level. Characterization of the mutations in 10 probands, including six with novel insertions, nonsense and splice site mutations, showed that the abnormal transcript was detectable in nine cases. The RPS19 mRNA and protein in CD34+ bone marrow cells identified haplo-insufficiency in three cases predicted to have one functional allele. Our data support the notion that, in addition to rare DBA patients with the deletion of one allele, the disease in certain other RPS19 mutant patients is because of RPS19 protein haplo-insufficiency.
先天性红细胞生成异常性贫血(DBA)是一种先天性红系造血功能低下疾病,临床异质性明显,其遗传基础仍不清楚。然而,近四分之一的患者在核糖体蛋白基因RPS19中存在多种突变,这为研究在某些情况下是否能证明RPS19蛋白单倍体不足提供了机会。为此,我们在81例DBA先证者(包括家族性和散发性)中鉴定出19例存在RPS19突变。我们在这19名先证者中发现了14种不同的插入、缺失、错义、无义及剪接位点突变,并在RNA水平上研究了10例患者的突变情况,在蛋白质水平上研究了3例患者的突变情况。对10例先证者(包括6例有新的插入、无义及剪接位点突变者)的突变特征分析表明,9例可检测到异常转录本。在预计有一个功能等位基因的3例CD34+骨髓细胞中,RPS19 mRNA和蛋白显示出单倍体不足。我们的数据支持这样一种观点,即除了罕见的一个等位基因缺失的DBA患者外,某些其他RPS19突变患者的疾病是由于RPS19蛋白单倍体不足所致。